IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
18.84
+0.21 (1.10%)
Apr 23, 2025, 4:00 PM EDT - Market closed
IDEAYA Biosciences Employees
IDEAYA Biosciences had 131 employees as of December 31, 2024. The number of employees increased by 7 or 5.65% compared to the previous year.
Employees
131
Change (1Y)
7
Growth (1Y)
5.65%
Revenue / Employee
$53,435
Profits / Employee
-$2,095,244
Market Cap
1.65B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
IDYA News
- 7 days ago - Ideaya Biosciences: These Prices Are Probably Going To Look Cheap Sooner Than Later - Seeking Alpha
- 9 days ago - IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma - PRNewsWire
- 13 days ago - IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer - PRNewsWire
- 21 days ago - Why Ideaya Biosciences Is Down Despite Many Positives - Seeking Alpha
- 22 days ago - IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events - PRNewsWire
- 23 days ago - IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma - PRNewsWire
- 26 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor - PRNewsWire